Dyne Therapeutics (NASDAQ:DYN) Director Jason Rhodes Sells 73,108 Shares

Dyne Therapeutics, Inc. (NASDAQ:DYN) Director Jason Rhodes sold 73,108 shares of the firm’s stock in a transaction that occurred on Thursday, April 23rd. The stock was sold at an average price of $19.19, for a total transaction of $1,402,942.52. Following the transaction, the director owned 11,286 shares in the company, valued at approximately $216,578.34. This trade represents a 86.63% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Dyne Therapeutics Stock Performance

Shares of Dyne Therapeutics stock traded down $0.22 during trading on Monday, reaching $18.04. The company’s stock had a trading volume of 1,718,516 shares, compared to its average volume of 2,147,507. The company has a 50-day moving average price of $17.69 and a two-hundred day moving average price of $18.46. Dyne Therapeutics, Inc. has a fifty-two week low of $8.06 and a fifty-two week high of $25.00. The firm has a market cap of $2.98 billion, a PE ratio of -5.10 and a beta of 1.29. The company has a current ratio of 22.25, a quick ratio of 22.25 and a debt-to-equity ratio of 0.15.

Dyne Therapeutics (NASDAQ:DYN) last issued its quarterly earnings data on Monday, March 2nd. The company reported ($0.76) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.74) by ($0.02). On average, analysts forecast that Dyne Therapeutics, Inc. will post -2.94 EPS for the current year.

Institutional Investors Weigh In On Dyne Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the company. T. Rowe Price Investment Management Inc. lifted its stake in shares of Dyne Therapeutics by 523.7% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 17,540,089 shares of the company’s stock valued at $343,085,000 after buying an additional 14,727,667 shares during the period. Vanguard Group Inc. grew its stake in Dyne Therapeutics by 14.9% in the 4th quarter. Vanguard Group Inc. now owns 11,215,565 shares of the company’s stock worth $219,376,000 after acquiring an additional 1,455,151 shares during the period. State Street Corp grew its stake in Dyne Therapeutics by 27.0% in the 4th quarter. State Street Corp now owns 6,692,745 shares of the company’s stock worth $130,910,000 after acquiring an additional 1,423,828 shares during the period. Adage Capital Partners GP L.L.C. raised its holdings in Dyne Therapeutics by 45.5% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 5,172,000 shares of the company’s stock valued at $101,164,000 after acquiring an additional 1,618,000 shares during the last quarter. Finally, Orbis Allan Gray Ltd purchased a new position in shares of Dyne Therapeutics during the 4th quarter worth $93,926,000. 96.68% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of brokerages have recently issued reports on DYN. Jefferies Financial Group reiterated a “buy” rating on shares of Dyne Therapeutics in a research note on Monday, March 9th. Wall Street Zen lowered Dyne Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, December 28th. Chardan Capital reiterated a “buy” rating and set a $38.00 target price on shares of Dyne Therapeutics in a research report on Monday, March 9th. JPMorgan Chase & Co. reduced their price target on Dyne Therapeutics from $17.00 to $16.00 and set a “neutral” rating for the company in a report on Tuesday, January 20th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Dyne Therapeutics in a report on Monday, April 20th. Three analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Dyne Therapeutics has an average rating of “Moderate Buy” and an average target price of $35.14.

Dyne Therapeutics Company Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.